Efficacy and safety of chemotherapy combined with bevacizumab in Chinese patients with metastatic colorectal cancer: A prospective, multicenter, observational, non-interventional phase IV trial

OBJECTIVE: Bevacizumab has an important and evolving role in improving outcomes in patients with metastatic colorectal cancer (mCRC) worldwide and was approved in China in 2010. However, there are limited real-world data on the efficacy and safety of chemotherapy regimens combined with bevacizumab i...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Fenghua, Dai, Guanghai, Deng, Yanhong, Tang, Yong, Wang, Wei, Niu, Zuoxing, Bi, Feng, Zhu, Liangjun, Guo, Zengqing, Yan, Jin, Hu, Bing, Tao, Min, Yang, Shujun, Zhang, Suzhan, Wen, Lu, Xu, Ruihua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8435824/
https://www.ncbi.nlm.nih.gov/pubmed/34584374
http://dx.doi.org/10.21147/j.issn.1000-9604.2021.04.06

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8435824/
https://www.ncbi.nlm.nih.gov/pubmed/34584374
http://dx.doi.org/10.21147/j.issn.1000-9604.2021.04.06

Ejemplares similares